Sintilimab, Stereotactic Body Radiotherapy and Granulocyte-macrophage Colony Stimulating Factor as Second-line Therapy for Advanced Non-small Cell Lung Cancer: Safety Run-in Results of a Multicenter, Single-arm, Phase II Trial
Research Square (Research Square)